Kamada - High Quality Pharmaceuticals

Mar. 5, 2014

Kamada Initiates Phase 2/3 Clinical Trial of Glassia to Treat Newly Diagnosed Pediatric Patients with Type 1 Diabetes

Mar. 4, 2014

Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies

Upcoming Event

Kamada to participate at the 20th International Plasma Protein Congress (IPPC)
Mar. 11-12, 2014

High Quality Pharmaceuticals

Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology.
Kamada´s product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide.

Alpha-1

Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic condition which can cause serious liver disease in children and liver and/or lung disease in adults. The most common clinical presentation of Alpha-1 Deficiency is lung disease. That is the reason it is also called "Inherited Emphysema" or "Genetic COPD".

High Quality Pharmaceuticals

Alpha-1

Kamada Highlights Video